Does a diagnosis of metabolic syndrome have value in clinical practice?

American Journal of Clinical Nutrition

Volumn 83, Issue 6, 2006, Pages 1248-1251

  Grundy, Scott M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Blood pressure; Cardiovascular disease; Diabetes; Metabolic syndrome; Risk factors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; NICOTINIC ACID; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIAGNOSTIC TEST; DRUG APPROVAL; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; EXERCISE; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; REVIEW; SMOKING CESSATION; THROMBOSIS; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; GENETICS; MIDDLE AGED; NOTE; RISK FACTOR;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS;

EID: 33745592823     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/83.6.1248     Document Type: Review

References (19)

1. Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 2006;83:1237-47.
2. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of sDiabetes. Diabetes Care 2005;28:2289-304.
3. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: a statement for health care professionals. An American Heart Association/National Heart Lung and Blood Institute scientific statement. Circulation 2005;112:2735-52.
4. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
5. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993;44:121-31.
6. Einhorn D. ACE position statement on insulin resistance syndrome. Endocrinol Pract 2003;9:237-52.
7. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
8. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation 2002;106:3143-421.
9. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3.
10. Alberti KGMM, Zimmet P, Shaw J; the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.
11. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. Third National Health and Nutrition Examination Survey (NHANESIII); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-4.
12. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care 2003;26:3153-9.
13. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
14. Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL Study: a randomized controlled trial. JAMA 2005;294:2437-45.
15. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. (Published erratum appears in Circulation 2004;110:763.)
16. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998;158:1855-67.
17. Julius S, Majahalme S, Palatini P. Antihypertensive treatment of patients with diabetes and hypertension. Am J Hypertens 2001;14(11 Pt 2):310S-6S.
18. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355-61.
19. Tuck ML. Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system. Curr Hypertens Rep 2005;7:240-3.